Bio + Health

How We Live Longer

Daisy Wolf and Vijay Pande Posted June 19, 2024

When we think about improving our health, we often focus on moonshot ideas like curing cancer. But—as vitally important as that is—curing all cancer would increase Americans’ lifespan by just three years, still leaving us lagging behind other developed nations.

Most poor health outcomes are from diseases we already know how to prevent or cure. We just can’t manage to improve overall health because (1) the healthcare system is exceedingly hard to navigate, making it difficult to proactively monitor one’s health and get care, even for those who are highly motivated, and (2) most people struggle to make optimal behavioral choices in terms of diet, exercise, and sleep.

These are both issues of consumer experience, not science or medicine. Behavior change might sound like a cultural issue—but the best consumer companies change the behavior of millions, if not billions, of people.

The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.

If you fix consumer’s healthcare experience, you can make it easier and more enjoyable for people to monitor their health (nearly 30% of Americans don’t see a primary care provider), to take their medication (50% of Americans don’t take their prescribed medications), and to make healthier lifestyle choices (88% of Americans are metabolically unhealthy).

While these changes sound simple—and would add many years to Americans’ lives—no healthcare company has been able to help us make these changes.

The opportunity is immense: we need companies to reinvent consumer health. We define consumer health broadly—referring not just to companies that prescribe medications (e.g. Ro) or provide telemedicine (e.g. Teladoc) direct-to-consumer on the internet. A consumer health company need not be direct-to-consumer, cash pay, or even a provider of services. It simply must offer engaging, proactive consumer experiences that traditional healthcare has failed to provide.

Any company who can do these things will improve our health, reduce healthcare costs, and wield a whole lot of power. The terrible user experience that exists today in healthcare is a problem, but it’s also a huge opportunity.

The role of outsiders

So who is going to improve healthcare for consumers?

Our bet is that it will be outsiders to healthcare. While healthcare insiders are well poised to build enterprise healthcare businesses due to the inside-baseball of the system, we believe consumer health is going to be fixed by outsiders.

History teaches us that major step changes in consumer experiences—across industries—are generally driven by outsiders who fundamentally reimagine how things could work. Consider the following examples:

  • Retail: It was Amazon—not a traditional retailer like Walmart—that enabled anyone to have anything they could possibly dream of shipped to their home.
  • Transportation: It was Uber and Lyft—not a taxi or limo service—that gave us instantaneous access to rides.
  • Telecomm: It was Spotify—not Universal or Sony—that gave us unlimited access to music for a low price.
  • Payments: It was PayPal—not a traditional bank—that revolutionized online payments and digital wallets.

Furthermore, there are not many healthcare insiders who have the consumer chops necessary to build magical healthcare experiences. Healthcare incumbents have not prioritized the consumer experience because they view payors—not consumers—as their end customers, and as result the industry hasn’t bred consumer talent. Conversely, outsiders—particularly from tech—have obsessed over consumer experience, and to great success. People that were trained at Apple, Meta, Google, Amazon, Tiktok, Spotify—the list goes on—have spent their careers building experiences so compelling that they’ve fundamentally changed consumer behavior. This isn’t to say that only outsiders can build transformational healthcare companies; in fact, we’re most excited by companies that blend an outsider’s perspective with an insider’s knowledge of the healthcare industry.

.

In the examples from other industries, outsider founders were willing to play outside of the rules of the incumbent system, eventually threatening to replace the system itself. But radically changing consumer experience in healthcare entails towing a slightly finer line: almost every healthcare startup needs to “play nice” with the incumbent system to some degree. Even disruptors aiming to overhaul the healthcare system must engage with existing systems and often intractable industry incumbents as they build and deploy their own solutions. Alternatively, outsiders could permanently integrate with traditional systems, providing consumer engagement services that incumbents struggle with: a number of successful startups offer patient-engagement-as-a-service to insurers and hospitals, driving improved outcomes and cost savings through effective consumer engagement.

Now is the time

In the last year, we’ve sensed a change. Inspired by a new wave of longevity, concierge medicine, and diagnostic companies, consumers are taking their health into their own hands, flocking to get extensive preventative testing—from comprehensive blood tests and full-body MRIs to cancer screenings and genetic panels—to fully understand what is happening in their bodies. Many of these companies are founded by outsiders and operating outside the bounds of traditional health insurance and health systems.

Incumbent, old-school healthcare generally opposes this health empowerment movement, believing it could cause unnecessary health scares and drive up healthcare spend. But these regular tests could save your life, if you can access them with appropriate context and without breaking the bank. New blood tests can catch early stage cancer and full body MRIs can spot malignant tumors. While we understand some of the incumbents’ concerns, it’s hard to believe that the side of more data and transparency will not win. Concierge medicine shouldn’t be condemned; it should be democratized. Outsiders will likely drive this democratization.

The biggest step changes in human health lie not just in curing every disease, but in revolutionizing the consumer experience. We can markedly improve our health by simplifying health monitoring, ensuring medication adherence, and promoting healthier lifestyles—all areas where traditional healthcare companies have struggled. Tech and consumer-focused disruptors, whose expertise is in user engagement and behavioral change, are well-positioned to reimagine and democratize care, leading to better health outcomes, lower costs, and an empowered population. The challenge is immense, but so is the opportunity.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Growth

new Good news: AI Will Eat Application Software

Alex Immerman and Santiago Rodriguez
Bio + Health

Infinite Healthcare: What’s It Worth?

Jay Rughani, Jane Rhee, and Julie Yoo
General

Forward-deployed Job Titles

Tom Hollands

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.